The disclosure relates to use of the HE4/HE4a marker(s) together with one or more other markers to assess ovarian cancers in a patient.

Efficient harvesting of cells, cell fragments, free nuclei, and DNA material from female reproductive system is made possible by processing gelatinous part of cervical mucus. Rinsing may be used to separate the gelatinous part of cervical mucus from the remainder of the cervical mucus sample.

The invention relates to a device and a method for cancer detection and screening, based on analysis of Volatile Organic Compounds emitted by certain cancerous tumors. The device and method provide high sensitivity and specificity analyses. The sample to be analysed may be e.g. blood or blood plasma. In one aspect, the invention is directed towards detection of or screening for gynaecological cancers, e.g. ovarian cancer. Particularly, the device comprises the following parts: a sample holder for a fluid or solid body sample; an air inlet; a detector tube comprising 44-164 sensors; optionally an individual potentiometer connected to each sensor of the detector tube; an analogue to digital signal converter; four control cards; a computer-based program for the registration and statistical calculation of results; and an electricity source.

USP14 is a biomarker for recurrent disease and inhibition of USP14 is of therapeutic benefit for women with endometrial or ovarian cancer.

The present disclosure relates to methods of determining a treatment course of action. In particular, the present disclosure relates to mutations in the gene encoding estrogen receptor and their association with responsiveness to estrogen therapies for cancer.

An in vitro method for diagnosing a urological cancer comprising the comparison of a secretome of isolated cells from a urine sample from a patient to be diagnosed with respect: either to a reference secretome obtained from secretions of healthy isolated cells from a urine sample from a healthy person, or to a reference secretome obtained from secretions of healthy cells which are derivatives of standard cell line cultures, characteristic of a determined urological organ, the secretome and the reference secretome being constituted of all the components forming the respective secretions thereof.

Systems and methods for evaluating a gynecological disorder in a subject is disclosed. A biological fluid sample is obtained from the subject. Protein fractions are purified from the biological fluid sample, thereby obtaining a protein preparation. For each protein in a set of proteins, a corresponding abundance value for the respective protein in the protein preparation is determined, thereby obtaining a protein abundance dataset for the subject. Using the protein abundance dataset, values for each of a set of protein abundance features are determined, thereby obtaining a feature dataset for the subject. The feature set is input into a classifier. The classifier is trained to distinguish between at least two states of the gynecological disorder based on at least the set of protein abundance features, thereby obtaining a probability or likelihood from the classifier that the subject has a particular state of a gynecological disorder.

Systems and methods for evaluating an ovarian or uterine disease condition in a subject are provided. A uterine lavage fluid sample from the subject is obtained. For each autoantibody species in a first set of autoantibody species, a corresponding abundance value for the respective autoantibody species in the uterine lavage fluid sample is determined, thereby obtaining an autoantibody abundance dataset for the subject. The autoantibody abundance dataset is input into a classifier trained to distinguish between at least two states of the ovarian or uterine disease condition based on at least abundance values for the first set of autoantibody species. The classifier thereby obtains a probability or likelihood that the subject has a particular state of an ovarian or uterine disease condition.

Disclosed herein are various methods for assessing the presence of gynecologic neoplasm or the malignancy of the gynecologic neoplasm, based on the hypermethylation of one or more marker genes.

The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of MMP9 in a uterine aspirate fluid sample from the female genital tract. The present invention further provides kits for the diagnosis of the disease.